Pfizer, CST team with Ventana in cancer personalised medicine pact related to candidates for Xalkori
This article was originally published in Scrip
Executive Summary
Roche subsidiary Ventana Medical Systems has signed a deal with Pfizer and licence agreement with Cell Signalling Technology to develop the first fully automated and standardised immunohistochemistry (IHC) companion diagnostic test for anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements. The test is intended to identify non-small cell lung cancer patients with ALK gene rearrangements who may benefit from Pfizer’s Xalkori (crizotinib) approved for use in the US last August.